Selvita Signs Contract with Evestra

Selvita S.A. has announced signature of an agreement with Evestra GmbH (Germany) for the delivery of a series of drug metabolism, pharmacokinetic (DMPK) and physicochemical studies.

The contracted project involves a set up and implementation of drug metabolism and pharmacokinetics studies, including CYP inhibition, metabolic identification and stability, as well as oral bioavailability and pharmacokinetics assays, both in vitro and in vivo, accompanied by gentotoxicity testing.

“We are keen to take advantage of Selvita’s know-how to support the process of further development of our project. We’re reassured of the competences that Selvita’s team has and high quality of service they deliver. We truly hope this cooperation will provide a value added for Evestra.” – said Klaus Nickisch, Executive Vice President, Chief Scientific Officer, Evestra Inc.

“We are very glad that we can conduct this project for Evestra. Evestra’s choice to entrust Selvita with their project is not only a nobilitation for us, but also gives our research team a chance to show their potential and capabilities to run complex projects in yet another field of preclinical research” – said Dr Milosz Gruca, Selvita’s Head of Biology Department.